Akron is pleased to announce that it secured a strategic collaboration with Vivex Biomedical, Inc. on the use of its next-generation line of cryopreservation media, CryoNovo™.
Vivex Biomedical, Inc., from Marietta, GA, designs and develops innovative biologic products for regenerative medicine applications. Tracy Anderson, Vivex CEO, speaks to the imperative, "Vivex underscores its commitment to patient care in the confidence that only the highest quality products become therapeutic options. Our collaboration with Akron Biotech meets those standards of excellence."
Akron's glycerol-, serum- and DMSO-free cryoprotectant, CryoNovo™ T82, was developed as a non-toxic alternative to traditional DMSO-based cryopreservation media. CryoNovo™ T82 provides improved cell viability and functionality when used to preserve biological cells and tissues.
Akron's Claudia Zylberberg said, "We are extremely pleased to extend our new line of DMSO-free cryomedia toward exciting and important new applications, and the collaboration with Vivex is a prime example of the potential and significance of improved cryopreservation solutions which Akron pioneered."
CryoNovo™ T82 is used in the Vivex process of viable bone allograft preparation; retaining cell function, sustaining cell viability, and providing dependable cell identity that supports therapeutic intervention in orthopaedic and other regenerative medicine applications.